In Focus channel feed – Endpoints News

In Focus channel feed

‘If grippe condemns, the secondary infections execute’: What the coronavirus pandemic means for the field of antibiotics

6 years ago

Investing in the time of coronavirus: the good, the bad and the hopeful, as biotech VC firms close funds worth $3B

6 years ago

‘It’s like the tortoise and the hare’: A pandemic puts Sanofi’s $600M bet to the test

6 years ago

'Dramatic times': How did an $8B surge in NIH grants over five years change research on the ground (if at all)?

6 years ago

A 9/11-era Omaha facility, an old Ebola drug, and the ubiquitous Dr. Fauci: Inside the first US novel coronavirus trial

6 years ago

For two decades, a new vaccine technology has been slowly approaching prime time. Now, can it stop a pandemic?

6 years ago

He built a MERS treatment in 6 months and then the best Ebola drug. Now Christos Kyratsous turns his sights on Covid-19

6 years ago

Carl June on CRISPR, CAR–T and how the Vietnam War dropped him into medicine

6 years ago

Can we make the antibiotic market great again?

6 years ago

At #JPM20, two CEOs, two radically different therapies, and a fight to chase down sickle cell

6 years ago

#JPM20: After a year of NASH collapses, all eyes on two biotechs

6 years ago

Over a decade into the milestone boom, it's time to ask. Just how often do they really pay off?

6 years ago

Alzheimer's breakthrough? Not so fast — experts poke holes in data underlying China's surprise approval

6 years ago

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

7 years ago

Where does the science come from? The top 20 NIH-funded institutions in 2017

8 years ago

First page Previous page 5 6 78